521 related articles for article (PubMed ID: 18378613)
1. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction.
Sabatine MS; Morrow DA; Higgins LJ; MacGillivray C; Guo W; Bode C; Rifai N; Cannon CP; Gerszten RE; Lee RT
Circulation; 2008 Apr; 117(15):1936-44. PubMed ID: 18378613
[TBL] [Abstract][Full Text] [Related]
2. Interleukin 33 and ST2 in non-ST-elevation myocardial infarction: comparison with Global Registry of Acute Coronary Events Risk Scoring and NT-proBNP.
Dhillon OS; Narayan HK; Quinn PA; Squire IB; Davies JE; Ng LL
Am Heart J; 2011 Jun; 161(6):1163-70. PubMed ID: 21641364
[TBL] [Abstract][Full Text] [Related]
3. Multimarker Risk Stratification in Patients With Acute Myocardial Infarction.
O'Donoghue ML; Morrow DA; Cannon CP; Jarolim P; Desai NR; Sherwood MW; Murphy SA; Gerszten RE; Sabatine MS
J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27207959
[TBL] [Abstract][Full Text] [Related]
4. Plasma N-terminal fragment of the prohormone B-type natriuretic peptide concentrations in relation to time to treatment and Thrombolysis in Myocardial Infarction (TIMI) flow: a substudy of the Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT IV-PCI) trial.
Jarai R; Huber K; Bogaerts K; Droogne W; Ezekowitz J; Granger CB; Sinnaeve PR; Ross AM; Zeymer U; Armstrong PW; Van de Werf FJ;
Am Heart J; 2010 Jan; 159(1):131-40. PubMed ID: 20102879
[TBL] [Abstract][Full Text] [Related]
5. Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial.
Kohli P; Bonaca MP; Kakkar R; Kudinova AY; Scirica BM; Sabatine MS; Murphy SA; Braunwald E; Lee RT; Morrow DA
Clin Chem; 2012 Jan; 58(1):257-66. PubMed ID: 22096031
[TBL] [Abstract][Full Text] [Related]
6. A prospective cohort study of prognostic power of N-terminal probrain natriuretic peptide in patients with non-ST segment elevation acute coronary syndromes.
Ndrepepa G; Braun S; Mehilli J; Niemöller K; Schömig A; Kastrati A
Clin Res Cardiol; 2007 Jan; 96(1):30-7. PubMed ID: 17066344
[TBL] [Abstract][Full Text] [Related]
7. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction.
Santhanakrishnan R; Chong JP; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong R; Chai P; Low AF; Richards AM; Lam CS
Eur J Heart Fail; 2012 Dec; 14(12):1338-47. PubMed ID: 22869458
[TBL] [Abstract][Full Text] [Related]
8. Insights into the change in brain natriuretic peptide after ST-elevation myocardial infarction (STEMI): why should it be better than baseline?
Ezekowitz JA; Théroux P; Welsh R; Bata I; Webb J; Armstrong PW
Can J Physiol Pharmacol; 2007 Jan; 85(1):173-8. PubMed ID: 17487257
[TBL] [Abstract][Full Text] [Related]
9. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease.
Bibbins-Domingo K; Gupta R; Na B; Wu AH; Schiller NB; Whooley MA
JAMA; 2007 Jan; 297(2):169-76. PubMed ID: 17213400
[TBL] [Abstract][Full Text] [Related]
10. Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus.
Wolsk E; Claggett B; Pfeffer MA; Diaz R; Dickstein K; Gerstein HC; Lawson FC; Lewis EF; Maggioni AP; McMurray JJV; Probstfield JL; Riddle MC; Solomon SD; Tardif JC; Køber L
J Am Heart Assoc; 2017 May; 6(6):. PubMed ID: 28554908
[TBL] [Abstract][Full Text] [Related]
11. Dynamic changes in N-terminal pro-brain natriuretic peptide in acute coronary syndromes treated with percutaneous coronary intervention: a marker of ischemic burden, reperfusion and outcome.
Buchner S; Debl K; Barlage S; Griese D; Fredersdorf S; Jeron A; Lubnow M; Müller T; Muders F; Holmer S; Riegger GA; Luchner A
Clin Chem Lab Med; 2010 Jun; 48(6):875-81. PubMed ID: 20441480
[TBL] [Abstract][Full Text] [Related]
12. Combined use of the novel biomarkers high-sensitivity troponin T and ST2 for heart failure risk stratification vs conventional assessment.
Lupón J; de Antonio M; Galán A; Vila J; Zamora E; Urrutia A; Bayes-Genis A
Mayo Clin Proc; 2013 Mar; 88(3):234-43. PubMed ID: 23384388
[TBL] [Abstract][Full Text] [Related]
13. N-terminal pro-B-type natriuretic peptide in risk stratification after acute myocardial infarction in patients on long-term beta-adrenergic receptor blocker therapy.
Jonsson G; Abdelnoor M; Landaas S; Muller C; Kjeldsen SE; Os I; Westheim A
Cardiology; 2006; 106(2):102-8. PubMed ID: 16636540
[TBL] [Abstract][Full Text] [Related]
14. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3.
Bayes-Genis A; de Antonio M; Vila J; Peñafiel J; Galán A; Barallat J; Zamora E; Urrutia A; Lupón J
J Am Coll Cardiol; 2014 Jan; 63(2):158-66. PubMed ID: 24076531
[TBL] [Abstract][Full Text] [Related]
15. Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudy.
van Diepen S; Newby LK; Lopes RD; Stebbins A; Hasselblad V; James S; Roe MT; Ezekowitz JA; Moliterno DJ; Neumann FJ; Reist C; Mahaffey KW; Hochman JS; Hamm CW; Armstrong PW; Granger CB; Theroux P;
Int J Cardiol; 2013 Oct; 168(3):2127-33. PubMed ID: 23394896
[TBL] [Abstract][Full Text] [Related]
16. Noninvasive Prognostic Biomarkers for Left-Sided Heart Failure as Predictors of Survival in Pulmonary Arterial Hypertension.
Simpson CE; Damico RL; Hassoun PM; Martin LJ; Yang J; Nies MK; Vaidya RD; Brandal S; Pauciulo MW; Austin ED; Ivy DD; Nichols WC; Everett AD
Chest; 2020 Jun; 157(6):1606-1616. PubMed ID: 31987881
[TBL] [Abstract][Full Text] [Related]
17. Comparison of usefulness of N-terminal pro-brain natriuretic peptide as an independent predictor of cardiac function among admission cardiac serum biomarkers in patients with anterior wall versus nonanterior wall ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Haeck JD; Verouden NJ; Kuijt WJ; Koch KT; Van Straalen JP; Fischer J; Groenink M; Bilodeau L; Tijssen JG; Krucoff MW; De Winter RJ
Am J Cardiol; 2010 Apr; 105(8):1065-9. PubMed ID: 20381654
[TBL] [Abstract][Full Text] [Related]
18. N-terminal pro-brain natriuretic peptide and the timing, extent and mortality in ST elevation myocardial infarction.
Ezekowitz JA; Théroux P; Chang W; Mahaffey KW; Granger CB; Weaver WD; Hochman JS; Armstrong PW
Can J Cardiol; 2006 Apr; 22(5):393-7. PubMed ID: 16639474
[TBL] [Abstract][Full Text] [Related]
19. N-terminal probrain natriuretic peptide predicts adverse outcomes in acute-myocardial infarction even with preserved left ventricular ejection fraction.
Puri A; Narain VS; Mehrotra S; Dwivedi SK; Saran RK; Puri VK
Indian Heart J; 2006; 58(2):138-43. PubMed ID: 18989058
[TBL] [Abstract][Full Text] [Related]
20. Stabilization patterns and variability of hs-CRP, NT-proBNP and ST2 during 1 year after acute coronary syndrome admission: results of the BIOMArCS study.
van den Berg VJ; Umans VAWM; Brankovic M; Oemrawsingh RM; Asselbergs FW; van der Harst P; Hoefer IE; Kietselaer B; Crijns HJGM; Lenderink T; Oude Ophuis AJ; van Schaik RH; Kardys I; Boersma E; Akkerhuis KM;
Clin Chem Lab Med; 2020 Nov; 58(12):2099-2106. PubMed ID: 32383686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
